Reducing Complications of Influenza: Update on the Use of Antiviral Agents in Vulnerable Patients
| Overview / Abstract: |
Statement of Need
While influenza infection can be serious in any patient, those in high-risk groups are most susceptible to negative sequelae, including pneumonia, hospitalization, and death. Therefore, rapid identification and treatment of patients who are at high risk for influenza-related complications is strongly recommended by professional and government guidelines. This fast-paced, case-based activity will acquaint pharmacists with the latest updates on diagnostic testing and treatment (including the first novel antiviral therapy approved for the treatment of influenza in 20 years), so they are prepared to confidently counsel patients and colleagues on the best uses of these important strategies. Learning Objectives Identify appropriate candidates for antiviral therapy based on risk for influenza-related complications, in accordance with current guideline recommendations Determine the need for influenza treatment based on patient signs, symptoms, and accurate interpretation of appropriate diagnostic tests when necessary Evaluate the latest safety and efficacy data for novel antiviral treatment to determine its role in the influenza treatment paradigm |
|
Expiration |
Oct 28, 2020 |
|
Discipline(s) |
Pharmacy CPE |
|
Format |
Webinar / Webcast / Video |
|
Credits / Hours |
1.0 hours (0.10 CEUs) |
|
Accreditation |
ACPE |
|
Presenters / Authors / Faculty |
Jason E. Bowling, MD, FIDSA James S. Lewis II, PharmD, FIDSA |
|
Activity Specialities / Related Topics |
Infectious Disease |
|
Sponsors / Supporters / Grant Providers |
This activity is supported by an educational grant from Genentech, Inc. |
|
Keywords / Search Terms |
Paradigm Medical Communications, LLC. Influenza, Pharmacists, Pharmacy Tech , Health System Pharmacist, Hospital Pharmacist, Infectious Disease Free CE CME |
|